Nothing Special   »   [go: up one dir, main page]

NO944577L - Hemming av effekten av amyloidogene proteiner - Google Patents

Hemming av effekten av amyloidogene proteiner

Info

Publication number
NO944577L
NO944577L NO944577A NO944577A NO944577L NO 944577 L NO944577 L NO 944577L NO 944577 A NO944577 A NO 944577A NO 944577 A NO944577 A NO 944577A NO 944577 L NO944577 L NO 944577L
Authority
NO
Norway
Prior art keywords
inhibition
effect
amyloidogenic proteins
pperldino
amyloldogenic
Prior art date
Application number
NO944577A
Other languages
English (en)
Other versions
NO944577D0 (no
Inventor
William Henry Walker Lunn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944577D0 publication Critical patent/NO944577D0/no
Publication of NO944577L publication Critical patent/NO944577L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Anvendelse av en forbindelse med formelen OCH;CH; ¿R: (D hvor R1 og R3 uavhengig er hydrogen, -C-CH3, ¿ C¿ (q-Cfcalkyl), eller ¿C¿ Ar, hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldlno og plperldino; eller et farmasøytisk akseptabelt salt eller solvat derav, l fremstillingen av et medikament som er nyttig for hemming av produksjon av amyloldogent protein.
NO944577A 1993-12-01 1994-11-29 Hemming av effekten av amyloidogene proteiner NO944577L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/160,379 US6489355B2 (en) 1993-12-01 1993-12-01 Methods of inhibiting the effects of amyloidogenic proteins

Publications (2)

Publication Number Publication Date
NO944577D0 NO944577D0 (no) 1994-11-29
NO944577L true NO944577L (no) 1995-06-02

Family

ID=22576649

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944577A NO944577L (no) 1993-12-01 1994-11-29 Hemming av effekten av amyloidogene proteiner

Country Status (14)

Country Link
US (1) US6489355B2 (no)
EP (1) EP0663209A3 (no)
JP (1) JPH07188010A (no)
KR (1) KR950016720A (no)
CN (1) CN1109750A (no)
AU (1) AU673961B2 (no)
CA (1) CA2136789A1 (no)
CZ (1) CZ293194A3 (no)
HU (1) HUT72297A (no)
IL (1) IL111790A (no)
NO (1) NO944577L (no)
NZ (1) NZ270008A (no)
UA (1) UA26459C2 (no)
ZA (1) ZA949404B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
WO1999065489A1 (en) * 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
US8362066B2 (en) * 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
CN108186678A (zh) * 2018-01-10 2018-06-22 天津科技大学 羟基化碳纳米管在制备抑制β-淀粉样蛋白聚集的药物的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5145892A (en) * 1985-12-19 1992-09-08 Chisso Corporation Polypropylene resin composition
US5075321A (en) 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US4960815A (en) * 1988-09-22 1990-10-02 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives
US5081304A (en) * 1988-09-22 1992-01-14 Warner-Lambert Company Isotopically-labeled polycyclic amine derivatives
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
GB9002834D0 (en) * 1990-02-08 1990-04-04 Ici America Inc Compounds
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5175164A (en) * 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5192220A (en) * 1992-01-31 1993-03-09 Amp Inc. Dual readout extended socket
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5288249A (en) * 1992-09-02 1994-02-22 Cooper Industries, Inc. Base for cartridge lamp
US5252524A (en) * 1992-10-16 1993-10-12 Corning Incorporated Polarizing glasses
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法

Also Published As

Publication number Publication date
KR950016720A (ko) 1995-07-20
CA2136789A1 (en) 1995-06-02
NO944577D0 (no) 1994-11-29
EP0663209A3 (en) 1995-10-11
AU7909394A (en) 1995-06-08
CZ293194A3 (en) 1995-07-12
UA26459C2 (uk) 1999-08-30
EP0663209A2 (en) 1995-07-19
NZ270008A (en) 1997-07-27
CN1109750A (zh) 1995-10-11
IL111790A (en) 1998-10-30
JPH07188010A (ja) 1995-07-25
HU9403422D0 (en) 1995-02-28
US6489355B2 (en) 2002-12-03
IL111790A0 (en) 1995-01-24
AU673961B2 (en) 1996-11-28
US20010051368A1 (en) 2001-12-13
HUT72297A (en) 1996-04-29
ZA949404B (en) 1996-05-28

Similar Documents

Publication Publication Date Title
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
WO2003055441A3 (en) Medicaments
DK0664126T3 (da) Hæmning af trombin
NO308248B1 (no) Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
GB9211172D0 (en) Compounds
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
DK0659416T3 (da) Inhibering af seborE og acne
UA39941C2 (uk) Засіб для інгібування окислення ліпопротеїну низької щільності, засіб для приглушення атеросклерозу та засіб для приглушення ішемічної хвороби серця атеросклеротичного походження
DK5386D0 (da) Arylcyklobutylaminer og laegemiddelpraeparat indeholdende en saadan forbindelse
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO814113L (no) 2-oksoazetidinderivater og fremgangsmaate for deres fremstilling
NO944923L (no) Hemming av vektökning eller indusering av vekttap
GB9215844D0 (en) Novel compounds
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme